Compare RVPH & XPON Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RVPH | XPON |
|---|---|---|
| Founded | 2006 | 2016 |
| Country | United States | United States |
| Employees | 14 | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Electronic Components |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.2M | 7.8M |
| IPO Year | N/A | 2022 |
| Metric | RVPH | XPON |
|---|---|---|
| Price | $0.84 | $0.72 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 7 | 0 |
| Target Price | ★ $72.00 | N/A |
| AVG Volume (30 Days) | ★ 1.1M | 215.5K |
| Earning Date | 05-14-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 94.63 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $9,651,870.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 71.59 |
| 52 Week Low | $0.17 | $0.49 |
| 52 Week High | $3.11 | $5.50 |
| Indicator | RVPH | XPON |
|---|---|---|
| Relative Strength Index (RSI) | 48.18 | 60.77 |
| Support Level | $0.24 | $0.65 |
| Resistance Level | $0.99 | $0.77 |
| Average True Range (ATR) | 0.12 | 0.05 |
| MACD | -0.02 | 0.02 |
| Stochastic Oscillator | 67.10 | 99.84 |
Reviva Pharmaceuticals Holdings Inc is a late-stage pharmaceutical company that discovers, develops, and seeks to commercialize therapeutics for diseases. The current pipeline of the company focuses on the central nervous system, inflammatory, and cardiometabolic diseases. The company uses a chemical genomics-driven technology platform and proprietary chemistry to develop new medicines. The company's pipeline currently has two drug candidates, Brilaroxazine (RP5063) which is intended to treat multiple neuropsychiatric indications, including schizophrenia, bipolar disorder, depressive disorder, attention-deficit/hyperactivity disorder, behavioral and psychotic symptoms of dementia or Alzheimer's disease and Parkinson's disease psychosis and its other drug candidate is RP1208.
Expion360 Inc is focused on the design, assembly, manufacturing, and sales of lithium iron phosphate (LiFePO4) batteries and supporting accessories for recreational vehicles (RV's) and marine applications with plans to expand into home energy storage products and industrial applications. Its product offerings include some of the minimal-footprint batteries in the RV & Marine industry.